Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Radiation Oncology
Published in: Radiation Oncology 1/2015

Open Access 01-12-2015 | Research

Acute toxicity profile of craniospinal irradiation with intensity-modulated radiation therapy in children with medulloblastoma: A prospective analysis

Authors: Maurice C. Cox, Johannes M. Kusters, Corrie E. Gidding, Jolanda H. Schieving, Erik J. van Lindert, Johannes H. Kaanders, Geert O. Janssens

Published in: Radiation Oncology | Issue 1/2015

Login to get access

Abstract

Background

To report on the acute toxicity in children with medulloblastoma undergoing intensity-modulated radiation therapy (IMRT) with daily intrafractionally modulated junctions.

Methods

Newly diagnosed patients, aged 3–21, with standard-risk (SR) or high-risk (HR) medulloblastoma were eligible. A dose of 23.4 or 36.0Gy in daily fractions of 1.8Gy was prescribed to the craniospinal axis, followed by a boost to the primary tumor bed (54 or 55.8Gy) and metastases (39.6–55.8Gy), when indicated. Weekly, an intravenous bolus of vincristine was combined for patients with SR medulloblastoma and patients participating in the COG-ACNS-0332 study. Common toxicity criteria (CTC, version 2.0) focusing on skin, alopecia, voice changes, conjunctivitis, anorexia, dysphagia, gastro-intestinal symptoms, headache, fatigue and hematological changes were scored weekly during radiotherapy.

Results

From 2010 to 2014, data from 15 consecutive patients (SR, n = 7; HR, n = 8) were collected. Within 72 h from onset of treatment, vomiting (66 %) and headache (46 %) occurred. During week 3 of treatment, a peak incidence in constipation (33 %) and abdominal pain/cramping (40 %) was observed, but only in the subgroup of patients (n = 9) receiving vincristine (constipation: 56 vs 0 %, P = .04; pain/cramping: 67 vs 0 %, P = .03). At week 6, 73 % of the patients developed faint erythema of the cranial skin with dry desquamation (40 %) or moist desquamation confined to the skin folds of the auricle (33 %). No reaction of the skin overlying the spinal target volume was observed.

Conclusions

Headache at onset and gastro-intestinal toxicity, especially in patients receiving weekly vincristine, were the major complaints of patients with medulloblastoma undergoing craniospinal irradiation with IMRT.
Literature
1.
Gajjar A, Chintagumpala M, Ashley D, Kellie S, Kun LE, Merchant TE, et al. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): Long-term results from a prospective, multicentre trial. Lancet Oncol. 2006;7:813–20.CrossRefPubMed
2.
Packer RJ, Gajjar A, Vezina G, Rorke-Adams L, Burger PC, Robertson PL, et al. Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol. 2006;24:4202–8.CrossRefPubMed
3.
Pizer BL, Weston CL, Robinson KJ, Ellison DW, Ironside J, Saran F, et al. Analysis of patients with supratentorial primitive neuro-ectodermal tumours entered into the SIOP/UKCCSG PNET 3 study. Eur J Cancer. 2006;42:1120–8.CrossRefPubMed
4.
Calaminus G, Bamberg M, Jürgens H, Kortmann RD, Sörensen N, Wiestler OD, et al. Impact of surgery, chemotherapy and irradiation on long term outcome of intracranial malignant non-germinomatous germ cell tumors: Results of the German Cooperative trial MAKEI 89. Klin Padiatr. 2004;216:141–9.CrossRefPubMed
5.
Tekautz TM, Fuller CE, Blaney S, Fouladi M, Broniscer A, Merchant TE, et al. Atypical teratoid/rhabdoid tumors (ATRT): Improved survival in children 3 years of age and older with radiation therapy and high-dose alkylator-based chemotherapy. J Clin Oncol. 2005;1(23):1491–9.CrossRef
6.
Merchant TE, Boop FA, Kun LE, Sanford RA. A retrospective study of surgery and reirradiation for recurrent ependymoma. Int J Radiat Oncol Biol Phys. 2008;1(71):87–97.CrossRef
7.
Ostrom QT, Gittleman H, Farah P, Ondracek A, Chen Y, Wolinsky Y, et al. CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006–2010. Neuro Oncol. 2013;15:646–7.CrossRef
8.
Kaatsch P, Rickert CH, Kühl J, Schüz J, Michaelis J. Population-based epidemiologic data on brain tumors in German children. Cancer. 2001;92:3155–64.CrossRefPubMed
9.
Zeltzer PM, Boyett JM, Finlay JL, Albright AL, Rorke LB, Milstein JM, et al. Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: Conclusions from the Children’s Cancer Group 921 randomized phase III study. J Clin Oncol. 1999;17(3):832–45.PubMed
10.
Children’s Oncology Group COG-ACNS-0332 trial (NCT00392327): Efficacy of carboplatin administered concomitantly with radiation and isoretinoin as a pro-apoptotic agent in other than average risk medulloblastoma/PNET patients. A groupwide phase III study.
11.
Tatcher M, Glicksman A. Field matching considerations in craniospinal irradiation. Int J Radiat Oncol Biol Phys. 1989;17:865–9.CrossRefPubMed
12.
Parker WA, Freeman CR. A simple technique for craniospinal radiotherapy in the supine position. Radiother Oncol. 2006;78:217–22.CrossRefPubMed
13.
Chang EL, Allen P, Wu C, Ater J, Kuttesch J, Maor MH. Acute toxicity and treatment interruption related to electron and photon craniospinal irradiation in pediatric patients treated at the University of Texas M.D. Anderson Cancer Center. Int J Rad Biol Phys. 2002;52:1008–16.CrossRef
14.
St Clair WH, Adams JA, Bues M, Fullerton BC, La Shell S, Kooy HM, et al. Advantage of protons compared to conventional X-ray or IMRT in the treatment of a pediatric patient with medulloblastoma. Int J Radiat Biol Phys. 2004;58:727–34.CrossRef
15.
Howell RM, Giebeler A, Koontz-Raisig W, Mahajan A, Etzel CJ, D’Amelio Jr AM, et al. Comparison of therapeutic dosimetric data from passively scattered proton and photon craniospinal irradiations for medulloblastoma. Radiat Oncol. 2012;7:116.PubMedCentralCrossRefPubMed
16.
Parker W, Filion E, Roberge D, Freeman CR. Intensity-modulated radiotherapy for craniospinal irradiation: Target volume considerations, dose constraints, and competing risks. Int J Rad Biol Phys. 2007;69:251–7.CrossRef
17.
Pai Panandiker A, Ning H, Likhacheva A, Ullman K, Arora B, Ondos J, et al. Craniospinal irradiation with spinal IMRT to improve target homogeneity. Int J Radiat Oncol Biol Phys. 2007;68:1402–9.CrossRefPubMed
18.
Kusters JM, Louwe RJ, van Kollenburg PG, Kunze-Busch MC, Gidding CE, van Lindert EJ, et al. Optimal normal tissue sparing in craniospinal axis irradiation using IMRT with daily intrafractionally modulated junction. Int J Radiat Oncol Biol Phys. 2011;81:1405–14.CrossRefPubMed
19.
Lopez Guerra JL, Marrone I, Jaen J, Bruna M, Sole C, Sanchez-Reyes A, et al. Outcome and toxicity using helical tomotherapy for craniospinal irradiation in pediatric medulloblastoma. Clin Transl Oncol. 2014;16:96–101.CrossRefPubMed
20.
Jefferies S, Rajan B, Ashley S, Traish D, Brada M. Haematological toxicity of cranio-spinal irradiation. Radiother Oncol. 1998;48:23–7.CrossRefPubMed
21.
Huang F, Parker W, Freeman CR. Feasibility and early outcomes of supine-position craniospinal irradiation. Pediatr Blood Cancer. 2010;54:322–5.PubMed
22.
Suneja G, Poorvu PD, Hill-Kayser C, Lustig RA. Acute toxicity of proton beam radiation for pediatric central nervous system malignancies. Pediatr Blood Cancer. 2013;60:1431–6.CrossRefPubMed
23.
Kortmann RD, Kühl J, Timmermann B, Mittler U, Urban C, Budach V, et al. Postoperative neoadjuvant chemotherapy before radiotherapy as compared to immediate radiotherapy followed by maintenance chemotherapy in the treatment of medulloblastoma in childhood: Results of the German prospective randomized trial HIT’91. Int J Radiat Oncol Biol Phys. 2000;46:269–79.CrossRefPubMed
24.
Packer RJ, Sutton LN, Elterman R, Lange B, Goldwein J, Nicholson HS, et al. Outcome for children with medulloblastoma treated with radiation and cisplatin, CCNU, and vincristine chemotherapy. J Neurosurg. 1994;81:690–8.CrossRefPubMed
25.
Sheline GE, Wara WM, Smith V. Therapeutic irradiation and brain injury. Int J Radiat Oncol Biol Phys. 1980;6:1215–28.CrossRefPubMed
26.
Roila F, Herrstedt J, Aapro M, Gralla RJ, Einhorn LH, Ballatori E, et al. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: Results of the Perugia consensus conference. Ann Oncol. 2010;21 Suppl 5:232–43.CrossRef
27.
Wong RK, Paul N, Ding K, Whitehead M, Brundage M, Fyles A, et al. 5-hydroxytryptamine-3 receptor antagonist with or without short-course dexamethasone in the prophylaxis of radiation induced emesis: A placebo-controlled randomized trial of the National Cancer Institute of Canada Clinical Trials Group (SC19). J Clin Oncol. 2006;24:3458–64.CrossRefPubMed
28.
Legha SS. Vincristine neurotoxicity: Pathophysiology and management. Med Toxicol. 1986;1:421–7.PubMed
29.
Perez EA, Hesketh P, Sandbach J, Reeves J, Chawla S, Markman M, et al. Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: A multicenter, double-blind, randomized parallel study. J Clin Oncol. 1998;16:754–60.PubMed
30.
31.
Lawenda BD, Gagne HM, Gierga DP, Niemierko A, Wong WM, Tarbell NJ, et al. Permanent alopecia after cranial irradiation: Dose-response relationship. Int J Radiat Oncol Biol Phys. 2004;60:879–87.CrossRefPubMed
32.
Taylor RE, Bailey CC, Robinson K, Weston CL, Ellison D, Ironside J, et al. Results of a randomized study of preradiation chemotherapy versus radiotherapy alone for nonmetastatic medulloblastoma: The International Society of Paediatric Oncology/United Kingdom Children’s Cancer Study Group PNET-3 Study. J Clin Oncol. 2003;21:1581–91.CrossRefPubMed
33.
Paulino AC, Wen BC, Mayr NA, Tannous R, Loew TW, Goldman FD, et al. Protracted radiotherapy treatment duration in medulloblastoma. Am J Clin Oncol. 2003;26:55–9.CrossRefPubMed
34.
Packer RJ, Zhou T, Holmes E, Vezina G, Gajjar A. Survival and secondary tumors in children with medulloblastoma receiving radiotherapy and adjuvant chemotherapy: Results of Children’s Oncology Group trial A9961. Neuro Oncol. 2013;15:97–103.PubMedCentralCrossRefPubMed
Metadata
Title
Acute toxicity profile of craniospinal irradiation with intensity-modulated radiation therapy in children with medulloblastoma: A prospective analysis
Authors
Maurice C. Cox
Johannes M. Kusters
Corrie E. Gidding
Jolanda H. Schieving
Erik J. van Lindert
Johannes H. Kaanders
Geert O. Janssens
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Radiation Oncology / Issue 1/2015
Electronic ISSN: 1748-717X
DOI
https://doi.org/10.1186/s13014-015-0547-9

Other articles of this Issue 1/2015

Radiation Oncology 1/2015 Go to the issue

Research

Parotid gland shrinkage during IMRT predicts the time to Xerostomia resolution

Research

Iodine-125 seed brachytherapy for early stage prostate cancer: a single-institution review

Review

Live cell imaging at the Munich ion microbeam SNAKE – a status report

Research

Dexamethasone administration during definitive radiation and temozolomide renders a poor prognosis in a retrospective analysis of newly diagnosed glioblastoma patients

Research

Impact of waiting time after surgery and overall time of postoperative radiochemotherapy on treatment outcome in glioblastoma multiforme

Research

Prognostic value of MRI-derived masticator space involvement in IMRT-treated nasopharyngeal carcinoma patients